Related Experiment Video

Updated: Aug 14, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

[Treatment of viral hepatitis in children]

Alemka Jaklin Kekez1

  • 1Referentni centar za djecju gastroenterologiju i prehranu, Klinika za djecje bolesti Zagreb, Zagreb, Hrvatska. alemkajaklin@net.hr

Acta Medica Croatica : Casopis Hravatske Akademije Medicinskih Znanosti
|December 31, 2005
PubMed

Insights

Treating chronic hepatitis B in children focuses on preventing complications. For chronic hepatitis C, combined interferon and ribavirin therapy is now recommended for eligible pediatric patients.

Area of Science:

  • Pediatric Gastroenterology and Hepatology
  • Viral Hepatitis Management
  • Clinical Therapeutics

Context:

  • Chronic hepatitis B and C infections pose significant health risks in children.
  • Treatment guidelines for pediatric viral hepatitis are evolving.
  • Current management strategies aim to prevent long-term complications.

Purpose:

  • To outline current treatment approaches for chronic hepatitis B and C in pediatric populations.
  • To identify candidates eligible for antiviral therapy.
  • To discuss the efficacy and recommendations for different treatment regimens.

Summary:

  • For chronic hepatitis B (HBV), treatment focuses on complication prevention in children over 2 years old with elevated transaminases and histologic evidence. Interferon alfa is preferred over lamivudine due to higher efficacy.
  • For chronic hepatitis C (HCV), treatment is recommended for children over 3 years with persistent transaminase elevation, histologic evidence, and significant fibrosis. Combined interferon alfa and ribavirin therapy is now the standard of care, showing better results than interferon alfa alone.
  • Ongoing research and clinical trials are crucial for establishing definitive treatment guidelines and improving outcomes for children with chronic viral hepatitis.

Impact:

  • Provides clarity on current pediatric hepatitis treatment standards.
  • Highlights the shift towards combination therapy for chronic hepatitis C.
  • Emphasizes the need for further research to refine treatment protocols and improve patient prognosis.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...